促性腺激素释放激素激动剂在年轻乳腺癌化疗患者卵巢功能保护中的研究进展  

Advances research of gonadotropin-releasing hormone agonist in the protection of ovarian function in young breast cancer patients undergoing chemotherapy

作　　者：王璐瑶 褚轶凡 谢佳新 杨殊琳 杨柳[1] 靳镭 岳静[1] Wang Luyao;Chu Yifan;Xie Jiaxin;Yang Shulin;Yang Liu;Jin Lei;Yue Jing(Reproductive Medicine Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院生殖医学中心,武汉430030

出　　处：《中华生殖与避孕杂志》2024年第8期853-857,共5页Chinese Journal of Reproduction and Contraception

基　　金：国家重点研发计划(2022YFC2702503);湖北省国际科技合作项目(2021EHB025)。

摘　　要：乳腺癌发病率呈逐年上升趋势, 化疗是延长年轻乳腺癌患者生存时间的有效治疗方式, 同时也会对卵巢造成不可逆损害。近年来, 越来越多的研究聚焦于促性腺激素释放激素激动剂(gonadotropin-releasing hormone agonist, GnRH-a)用于保护乳腺癌化疗患者的卵巢功能, 但研究结论尚有争议。本文从化疗对乳腺癌患者卵巢功能的影响, GnRH-a概述及保护卵巢功能机制, GnRH-a在乳腺癌患者化疗中卵巢功能保护的临床研究进展及相关问题4个方面进行阐述, 以期为临床诊疗和相关研究提供思路。The incidence of breast cancer is on the rise annually,and chemotherapy is potentially effective in prolonging the lifespan of young breast cancer patients which also irreversibly harm the ovaries.Recently,increasingly more studies have focused on the role of gonadotropin-releasing hormone agonist(GnRH-a)for protecting ovarian function in patients undergoing chemotherapy with disputable findings.This review addresses four perspectives including the impact of chemotherapy on ovarian function,the introduction of GnRH-a and the possible mechanism of protecting ovarian function,the advances of clinical research on the ovarian protection by GnRH-a in chemotherapy for patients with breast cancer and other related issues,with the aim of providing thoughts for clinical diagnosis and associated research.

关 键 词：乳腺肿瘤 化疗 生育力保护 促性腺激素释放激素激动剂 

分 类 号：R737.9[医药卫生—肿瘤]